Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies

Journal of Crohn's and Colitis

Volumn 8, Issue 6, 2014, Pages 469-479

  Fumery, Mathurin ^a   Xiaocang, Cao ^b,c   Dauchet, Luc ^c   Gower Rousseau, Corinne ^c   Peyrin Biroulet, Laurent ^d   Colombel, Jean Frédéric ^c,e  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIV LILLE   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Arterial thromboembolism; Cardiovascular mortality; Inflammatory bowel disease; Ischemic heart disease; Venous thromboembolism

Indexed keywords

ARTERIAL THROMBOEMBOLISM; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; DEEP VEIN THROMBOSIS; EMBASE; HOSPITALIZATION; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MEDLINE; MESENTERIC ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR DISEASES; COMPLICATION; META ANALYSIS; MORTALITY; MYOCARDIAL ISCHEMIA; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; MYOCARDIAL ISCHEMIA; PULMONARY EMBOLISM; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84899900631     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.09.021     Document Type: Review

References (71)

1. Danese S. S, A. Papa, S. Saibeni, A. Repici, A. Malesci, M. Vecchi, Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am. J. Gastroenterol. 2007, 102:174-186.
2. Bergen J.A., Barker N.W. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch. Intern. Med. 1936, 58:17-31.
3. Murthy S.K., Nguyen G.C. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am. J. Gastroenterol. 2011, 106:713-718.
4. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm. Bowel Dis. 2011, 17:471-478.
5. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352(16):1685-1695. (21).
6. Cao J.J., Arnold A.M., Manolio T.A., Polak J.F., Psaty B.M., Hirsch C.H., et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007, 116:32-38.
7. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaile J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008, 15(59):1690-1697.
8. Avina-Zubieta J.A., Thomas J., Sadatsafavi M. A.J Lehman, D. Lacaille, Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 2012, 71:1524-1529.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
10. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
11. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:100-129.
12. Altman D.G. Confidence intervals for the number needed to treat. BMJ 1998, 317:1309-1312.
13. R Development Core Team R: a language and environment for statistical computing 2012, R Foundation for Statistical Computing, Vienna, Austria, (URLhttp://www.R-project.org/).
14. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 2010, 36:1-48.
15. Bernstein C.N., Wajda A., Blanchard J.F. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 2008, 6:41-45.
16. Yarur A.J., Deshpande A.R., Pechman D.M., Tamariz L., Abreu M.T., Sussman D.A. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am. J. Gastroenterol. 2011, 106:741-747.
17. Osterman M.T., Yang Y.X., Brensinger C., Forde K.A., Lichtenstein G.R., Lewis J.D. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin. Gastroenterol. Hepatol. 2011, 9:875-880.
18. Haapamäki J., Roine R.P., Turunen U., Färkkilä M.A., Arkkila P.E. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J. Crohns Colitis 2011, 5:41-47.
19. Rungoe C., Basit S., Ranthe M.F., Wohlfahrt J., Langholz E., Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2012, 62:689-694.
20. Andersohn F., Waring M., Garbe E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm. Bowel Dis. 2010, 16:1387-1392.
21. Huerta C., Rivero E., Montoro M.A., García-Rodriguez L.A. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case control study. Aliment. Pharmacol. Ther. 2011, 33:969-978.
22. Inamdar S.S., Altafi S.S., Sultan S. Increased risk of coronary artery disease among patients with inflammatory bowel disease. Gastroenterology 2012, 142(Suppl. 1):792-793.
23. Kappelman M.D., Horvath-Puho E., Sandler R.S., Rubin D.T., Ullman T.A., Pedersen L., et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011, 60:937-943.
24. Grainge M.J., West J., Card T.R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010, 20(375):657-663.
25. Merrill A., Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch. Surg. 2012, 147:120-124.
26. Novacek G., Weltermann A., Sobala A., Tilg H., Petritsch W., Reinisch W., et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010, 139:779-787.
27. Miehsler W., Reinisch W., Valic E., Osterode W., Tillinger W., Feichtenschlager T., et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004, 53:542-548.
28. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 2001, 85:430-434.
29. Huerta C.C., Johansson S.S., Wallander M.A., García Rodríguez L.A. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch. Intern. Med. 2007, 167(14):935-943.
30. Sridhar A.R., Parasa S., Navaneethan U., Crowell M.D., Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J. Crohns Colitis 2011, 5:287-294.
31. Nguyen G.C., Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 2008, 103:2272-2280.
32. Saleh T., Matta F., Yaekoub A.Y., Danescu S., Stein P.D. Risk of venous thromboembolism with inflammatory bowel disease. Clin. Appl. Thromb. Hemost. 2011, 17:254-258.
33. Höie O., Schouten L.J., Wolters F.L., Solberg I.C., Riis L., Mouzas I.A., et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10years after diagnosis. Gut 2007, 56:497-503.
34. Romberg-Camps M., Kuiper E., Schouten L., Kester A., Hesselink-van de Kruijs M., Limonard C., et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm. Bowel Dis. 2010, 16:1397-1410.
35. Manninen P., Karvonen A.L., Huhtala H., Rasmussen M., Salo M., Mustaniemi L., et al. Mortality in ulcerative colitis and Crohn's disease A population-based study in Finland. J. Crohns Colitis 2012, 6:524-528.
36. Wolters F.L., Russel M.G., Sijbrandij J., Schouten L.J., Odes S., Riis L., et al. Crohn''s disease: increased mortality 10years after diagnosis in a Europe-wide population based cohort. Gut 2006, 55:510-518.
37. Jess T., Winther K.V., Munkholm P., Langholz E., Binder V. Mortality and causes of death in Crohn''s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002, 122:1808-1814.
38. Prior P., Gyde S., Cooke W.T., Waterhouse J.A., R.N. Mortality in Crohn''s disease. Gastroenterology 1981, 80:307-312.
39. Winther K.V., Jess T., Langholz E., Munkholm P., Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003, 125:1576-1582.
40. Gyde S., Prior P., Dew M.J., Saunders V., Waterhouse J.A., Allan R.N. Mortality in ulcerative colitis. Gastroenterology 1982, 83:36-43.
41. Davoli M., Prantera C., Berto E., Scribano ML M.L., D'Ippoliti D. Mortality among patients with ulcerative colitis: Rome 1970-1989. Eur. J. Epidemiol. 1997, 13:189-194.
42. Viscido A., Bagnardi V., G.C, Annese V., Frieri G., D'Arienzo A., et al. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study. Dig. Liver Dis. 2001, 33:686-692.
43. Ekbom A., Helmick C.G., Zack M., Holmberg L., Adami H.O., et al. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992, 103:954-960.
44. Masala G., Bagnoli S., Ceroti M., Saieva C., Trallori G., Zanna I., et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn''s disease patients: the Florence IBD study 1978-2001. Gut 2004, 53:1309-1313.
45. Jess T., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Tremaine W.J., Melton L.J., et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long-term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006, 55:1248-1254.
46. Persson P.G., Bernell O., Leijonmarck C.E., Farahmand B.Y., Hellers G., Ahlbom A., et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996, 110:1339-1345.
47. Jess T., Frisch M., Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin. Gastroenterol. Hepatol. 2013, 11:43-48.
48. Koutroubakis I.E. IBD: which patients with IBD are at risk of venous thromboembolism?. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:307-308.
49. Van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J. Crohns Colitis 2010, 4:63-101.
50. Van Assche G., Dignass A., Bokemeyer B., Danese S., Gionchetti P., Moser G., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J. Crohns Colitis 2012, 6:965-990.
51. Mismetti P., Laporte-Simitsidis S., Tardy B., Cucherat M., Buchmüller A., Juillard-Delsart D., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb. Haemost. 2000, 83:14-19.
52. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients Prophylaxis in Medical Patients with Enoxaparin Study Group. N. Engl. J. Med. 1999, 34:793-800.
53. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008, 358:2765-2775.
54. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
55. Papa A., Santoliquido A., Danese S., et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005, 1(22):839-846.
56. Broide E., Schopan A., Zaretsky M., et al. Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population. Dig Dis Sci 2011, 56:197-202.
57. Kayahan H., Sari I., Cullu N., et al. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci 2012, 57:2137-2143.
58. Aloi M., Tromba L., Di Nardo G., et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr 2012, 161:589-594.
59. Regueiro M., Kip K.E., Cheung O., et al. Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:42-47.
60. Kaptoge S., Di Angelantonio E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors Collaboration.
61. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
62. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002, 288:980-987.
63. Danese S., Katz J.A., Saibeni S., et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003, 52:1435-1441.
64. Lutgens E., Lievens D., Beckers L. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007, 17:118-123.
65. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
66. Dorn S.D., Sandler R.S. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007, 102:662-667.
67. Liao K.P., Solomon D.H. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology 2013, 52:45-52.
68. Birrenbach T., Böcker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004, 10:848-859.
69. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
70. Tinsley A., Naymagon S., Trindade A.J., et al. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013, 47:e1-e6.
71. Tinsley A., Naymagon S., Enomoto L., et al. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with severe ulcerative colitis. Inflamm Bowel Dis 2012, 18(Suppl. 1):S1-S127.